M
Martin Schrappe
Researcher at University of Kiel
Publications - 393
Citations - 26551
Martin Schrappe is an academic researcher from University of Kiel. The author has contributed to research in topics: Minimal residual disease & Childhood Acute Lymphoblastic Leukemia. The author has an hindex of 83, co-authored 355 publications receiving 22797 citations. Previous affiliations of Martin Schrappe include Genomatix.
Papers
More filters
Journal ArticleDOI
No association between the presence of killer-cell immunoglobulin-like receptor genes and susceptibility to childhood ALL
Lena Oevermann,Lena Oevermann,Matthias Firnkorn,Sebastian Michaelis,Simon Müller,Simon Müller,Elke Schaeffeler,Elke Schaeffeler,Martin Schrappe,Gunnar Cario,Martin Stanulla,Matthias Schwab,Matthias Schwab,Rupert Handgretinger,Markus Mezger +14 more
TL;DR: To the editor: Killer-cell immunoglobulin-like receptors (KIRs) play a pivotal role in immunosurveillance and reduction of relapse after hematopoietic stem cell transplantation in acute leukemia.
Journal ArticleDOI
Temporal changes of the incidence of childhood cancer in Germany during the COVID-19 pandemic: Updated analyses from the German Childhood Cancer Registry
TL;DR: This paper aims to demonstrate the efforts towards in-situ applicability of the EMMARM, which aims to provide real-time information about individual patients’ cancer progression and Kessler’s disease progression through a probabilistic process.
Journal ArticleDOI
Early Diagnosis and Molecular-Based Treatment of Very Highly Resistant Acute Lymphoblastic Leukemia in Childhood
Gunnar Cario,André Schrauder,Anja Moericke,Jean-Pierre Bourquin,Martin Schrappe,Martin Stanulla +5 more
TL;DR: Data is presented on gene expression profiling of HR patients performed in parallel to the ongoing extensive MRD analysis and shows that patients with a persistently high MRD load after the application of three intensive HR blocks were neither curable by chemotherapy alone nor by the addition of stem cell transplantation.
Journal ArticleDOI
Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets
Jessica I. Hoell,Jessica I. Hoell,Sebastian Ginzel,Michaela Kuhlen,Andreas Kloetgen,Michael Gombert,Ute Fischer,Daniel Hein,Salih Demir,Martin Stanulla,Martin Schrappe,Udo zur Stadt,Peter Bader,Florian Babor,Friedhelm R. Schuster,Brigitte Strahm,Julia Alten,Anja Moericke,Gabriele Escherich,Arend von Stackelberg,Ralf Thiele,Alice C. McHardy,Christina Peters,Beat Bornhauser,Jean-Pierre Bourquin,Stefan Krause,Juergen Enczmann,Lüder Hinrich Meyer,Cornelia Eckert,Cornelia Eckert,Arndt Borkhardt,Roland Meisel +31 more
TL;DR: It is found that post-allo-SCT ALL relapses display highly diverse and mostly patient-individual genetic lesions, and alterations in genes for which targeted therapies with novel agents are readily available are found.
Journal ArticleDOI
Time Point-Dependent Concordance of Flow Cytometry and RQ-PCR in the MRD Detection in Childhood ALL: The Experience of the AIEOP-BFM- ALL MRD Study Group
Giuseppe Gaipa,Giovanni Cazzaniga,Renate Panzer-Grümayer,Marinella Veltroni,Leonid Karawajew,Daniela Silvestri,Barbara Buldini,Richard Ratei,André Schrauder,Martin Schrappe,Wolf-Dieter Ludwig,Maria Grazia Valsecchi,Andrea Biondi,Michael Dworzak,Giuseppe Basso +14 more
TL;DR: Within BFM-based protocols, FCM cannot simply substitute the current PCR-based MRD risk stratification at the same TPs, and the recent implementation of further technical developments in the FCM procedure, are designed to increase the concordance rate.